Renal denervation for resistant hypertension using an irrigated radiofrequency balloon: 12-Month results from the Renal Hypertension Ablation System (RHAS) trial

EuroIntervention

Volumn 9, Issue 1, 2013, Pages 70-74

  Ormiston, John A ^a,b   Watson, Timothy ^b   Van Pelt, Niels ^c   Stewart, Ralph ^a,b   Stewart, James T ^a,b   White, Jonathon M ^b   Doughty, Robert N ^a,b   Stewart, Fiona ^a   Macdonald, Rhona ^a   Webster, Mark W I ^a,b  

^a Mercy Angiography ^*  (New Zealand)

^b AUCKLAND CITY HOSPITAL   (New Zealand)

^c Division of Medicine Emergency and Integrated Care   (New Zealand)

Author keywords

Hypertension; Radiofrequency ablation; Renal denervation

Indexed keywords

ANTIHYPERTENSIVE AGENT;

ADULT; ARTICLE; BALLOON; BALLOON CATHETER; CLINICAL ARTICLE; CLINICAL EFFECTIVENESS; CLINICAL TRIAL; DISEASE RESISTANCE; FEASIBILITY STUDY; FEMALE; GUIDE WIRE; HUMAN; HYPERTENSION; IRRIGATED RADIOFREQUENCY BALLOON; KIDNEY DENERVATION; MALE; PROSPECTIVE STUDY; RADIOFREQUENCY; RENAL ARTERY; RESISTANT HYPERTENSION; SAFETY; SYSTOLIC BLOOD PRESSURE; TREATMENT FAILURE;

ADULT; AGED; ANTIHYPERTENSIVE AGENTS; AUTONOMIC DENERVATION; BLOOD PRESSURE; CATHETER ABLATION; DRUG RESISTANCE; EQUIPMENT DESIGN; FEASIBILITY STUDIES; FEMALE; HUMANS; HYPERTENSION; KIDNEY; MALE; MIDDLE AGED; NEW ZEALAND; PROSPECTIVE STUDIES; THERAPEUTIC IRRIGATION; TIME FACTORS; TREATMENT OUTCOME;

EID: 84880031833     PISSN: 1774024X     EISSN: 19696213     Source Type: Journal    
DOI: 10.4244/EIJV9I1A11     Document Type: Article

References (13)

1. Symplicity HTN-2 Investigators, Esler MD, Krum H, Sobotka PA, Schlaich MP, Schmieder RE, Böhm M. Renal sympathetic denervation in patients with treatment-resistant hypertension (The Symplicity HTN-2 Trial): a randomised controlled trial. Lancet. 2010;376:1903-9.
2. Esler M, Krum H, Schmieder R, Bohm M. Renal sympathetic denervation for treatment of resistant hypertension: two-year update from the Symplicity HTN-2 randomized controlled trial. J Am Coll Cardiol. 2013;61(10-S).
3. Symplicity HTN-1 Investigators. Catheter-based renal sympathetic denervation for resistant hypertension: durability of blood pressure reduction out to 24 months. Hypertension. 2011;57:911-7.
4. Clement DL, De Buyzere ML, De Bacquer DA, de Leeuw PW, Duprez DA, Fagard RH, Gheeraert PJ, Missault LH, Braun JJ, Six RO, Van Der Niepen P, O'Brien E; Office versus Ambulatory Pressure Study Investigators. Prognostic value of ambulatory blood-pressure recordings in patients with treated hypertension. N Engl J Med. 2003;348:2407-15. (Pubitemid 36682819)
5. Staessen JA, Wang JG, Thijs L. Cardiovascular protection and blood pressure reduction: a meta-analysis. Lancet. 2001;358:1305-15. (Pubitemid 33016494)
6. Mahfoud F, Schlaich M, Kindermann I, Ukena C, Cremers B, Brandt MC, Hoppe UC, Vonend O, Rump LC, Sobotka PA, Krum H, Esler M, Böhm M. Effect of renal sympathetic denervation on glucose metabolism in patients with resistant hypertension: a pilot study. Circulation. 2011;123:1940-6.
7. Witkowski A, Prejbisz A, Florczak E, Kadziela J, Sliwinski P, Bielen P, Michalowska I, Kabat M, Warchol E, Januszewicz M, Narkiewicz K, Somers V, Sobotka P, Januszewicz A. Effects of renal sympathetic denervation on blood pressure, sleep apnea and glycemic control patients with resistant hypertension and sleep apnea. Hypertension. 2011;58:559-65.
8. Brandt MC, Mahfoud F, Reda S, Schirmer SH, Erdmann E, Böhm M, Hoppe UC. Renal sympathetic denervation reduces left ventricular hypertrophy and improves cardiac function in patients with resistant hypertension. J Am Coll Cardiol. 2012;59:901-9.
9. Sobotka PA, Krum H, Böhm M, Francis DP, Schlaich MP. The role of renal denervation in the treatment of heart failure. Curr Cardiol Rep. 2012;14:285-92.
10. Ormiston JA, Watson T, van Pelt N, Stewart R, Haworth P, Stewart JT, Webster MW. First-in-human use of the OneShot™ renal denervation system from Covidien. EuroIntervention. 2013;8:1090-4.
11. N akagawa H, Yamanashi WS, Pitha JV, Arruda M, Wang X, Ohtomo K, Beckman KJ, McClelland JH, Lazzara R, Jackman WM. Comparison of in vivo tissue temperature profile and lesion geometry for radiofrequency ablation with a saline-irrigated electrode versus temperature control in a canine thigh muscle preparation. Circulation. 1995;91:2264-73.
12. Bertog SC, Sobotka PA, Sievert H. Renal denervation for hypertension. JACC Cardiovasc Interv. 2012;5:249-58.
13. ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA. 2002;288:2981-98.